BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
On February 27, the US FDA approved BioMarin's supplemental Biologics License Application for PALYNZIQ, expanding its use to include adolescents aged 12 and older with phenylketonuria/PKU. This medication remains the only approved enzyme substitution therapy designed to reduce blood phenylalanine/Phe concentrations in patients with this rare genetic condition. The approval is particularly significant for teenagers, as the restrictive dietary management required for PKU often becomes difficult to maintain during adolescence, leading to potential neurocognitive issues if blood Phe levels remain uncontrolled. Data from the Phase 3 PEGASUS study supported this decision, demonstrating that PALYNZIQ achieved statistically significant reductions in blood Phe levels compared to diet alone. BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents Jirsak / shutterstock.com The safety profile for adolescents was found to be consistent with previous
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks [Yahoo! Finance]Yahoo! Finance
- How The BioMarin (BMRN) Story Is Shifting With Voxzogo Risks And The Amicus Deal [Yahoo! Finance]Yahoo! Finance
- BioMarin discontinues dosing in certain Voxzogo trials after safety concern [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (BMRN) had its "outperform" rating reaffirmed by Wolfe Research.MarketBeat
- BioMarin stops mid-stage trials of bone disorder treatment [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 2/23/26 - Beat
BMRN
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- BMRN's page on the SEC website